Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The data demonstrate that the company's next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, the sup-tRNAs provide durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The findings underscore the potential of Tevard's suppressor tRNA platform to address a broad range of genetic diseases caused by premature termination codons. In DMD models, the sup-tRNAs achieved approximately 100% restoration of full-length dystrophin, a critical protein missing in patients with Duchenne muscular dystrophy. This level of restoration suggests that the therapy could potentially halt or reverse disease progression. For DCM-TTNtv, the sup-tRNAs rescued full-length titin expression in a durable manner, offering hope for patients with this often-fatal heart condition.
Tevard's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. The presented programs highlight the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner. For more information, visit www.tevard.com.
To view the full announcement, including downloadable images, bios, and more, click here. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders, leveraging its suppressor tRNA platform to restore endogenous, full-length protein expression for diseases caused by premature termination codons.
